These results indicated that FMT could continuously monitor the growth of 22Rv1-iRFP-GFP orthotopic tumors, and that the tk gene driven by the PSA promoter (encapsulated by JCPyV VLP) could inhibit orthotopic prostate cancer growth. The gene discussed is TKT; the disease is prostate cancer.